

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/034741 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) *A61K 48/00* (2006.01)
A61K 38/00 (2006.01) *A61P 27/02* (2006.01)
A61K 38/17 (2006.01) *C07K 7/08* (2006.01)
A61K 38/22 (2006.01) *C07K 14/58* (2006.01)
A61K 47/68 (2017.01) *C07K 14/705* (2006.01)

(21) International Application Number:

PCT/US2024/041100

(22) International Filing Date:

06 August 2024 (06.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/531,202 07 August 2023 (07.08.2023) US
63/665,105 27 June 2024 (27.06.2024) US

(71) Applicant: **AVIRMAX BIOPHARMA INC.** [US/US];
25503 Whitesell Street, Hayward, California 94545 (US).

(72) Inventors: **LIU, Shengjiang**; 25503 Whitesell Street, Hay-
ward, California 94545 (US). **CHEN, Jianwu**; 25503
Whitesell Street, Hayward, California 94545 (US).


(74) Agent: **BARKER, Adrian** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS

Fig. 1



(57) Abstract: Described herein are compositions for modulating transgene expression of one or more therapeutics. In some aspects, an engineered polynucleotide comprising one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor. Also described herein are methods for using the compositions described herein for modulating transgene expression and for treating a disease or condition, in particular therapeutics for treating ocular diseases or inhibiting neovascularization.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*